Stock comparison
ANI Pharmaceuticals
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ANIP
ANI Pharmaceuticals
Market cap
$1.88B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ANIP | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 53C | 77B | LMAT |
| Benjamin Graham | 59D | 89A | LMAT |
| Philip Fisher | 58C | 81C | LMAT |
| Peter Lynch | 71C | 67B | ANIP |
| Joel Greenblatt | 44D | 56D | LMAT |
| Charlie Munger | 47D | 68D | LMAT |
| Terry Smith | 50D | 69D | LMAT |
Side-by-side metrics
| Metric | ANIP | LMAT |
|---|---|---|
| Market cap | $1.88B | $2.23B |
| P/E (TTM) | 18.5x | 37.1x |
| EV/EBIT | 22.4x | 36.6x |
| ROIC (TTM) | 8.17% | 9.43% |
| Gross margin | 65.94% | 72.39% |
| Net margin | 9.71% | 24.35% |
| Revenue CAGR 5y | 42.18% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 0.6x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ANIP leads on
- Revenue CAGR 5y42.18%vs 12.75%+70%
- P/E (TTM)18.5xvs 37.1x+50%
- EV/EBIT22.4xvs 36.6x+39%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 9.71%+60%
- Debt / Equity0.5xvs 0.6x+20%
- Market cap$2.23Bvs $1.88B+16%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.